When examining the total CTC count (CK+/Vimentin-/CD45-CTC plus CK+/Vimentin+/CD45-CTC plus CK-/Vimentin+/CD45-CTC), a significant difference was found between metastatic and non-metastatic disease (20.89±14.57 vs 8.428±5.858 / mL blood; P=0.0030) (Figure 7A). This evidence concerns the gene PTPRC and metastatic neoplasm.